Lian Jen, DO
Physical Medicine & Rehabilitation · Port Charlotte, FLNPI 1326031048
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 194 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AbbVie at 32.8% of the total. Among physical medicine & rehabilitation clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 194 payments — averaging $24.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Collegium Pharmaceutical, Inc.$694
- Indivior Inc.$525
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$426
- Pfizer$392
- Orexo US, Inc.$272
- plus $888 from 17 others
What the payments were for
- Food & beverage$4,735100%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 34 | $1,559 |
| Collegium Pharmaceutical, Inc. | 34 | $694 |
| Indivior Inc. | 23 | $525 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 29 | $426 |
| Pfizer | 20 | $392 |
| Orexo US, Inc. | 17 | $272 |
| Biohaven Pharmaceuticals, Inc. | 6 | $240 |
| Amgen | 1 | $116 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $81 |
| Redhill Biopharma Inc. | 4 | $69 |
| Eisai Inc. | 3 | $58 |
| Scilex Pharmaceuticals Inc. | 2 | $49 |
| Upsher-smith Laboratories LLC | 2 | $46 |
| Biodelivery Sciences International, Inc. | 3 | $43 |
| IBSA Pharma Inc. | 2 | $31 |
| Supernus Pharmaceuticals, Inc. | 2 | $31 |
| Daiichi Sankyo Inc. | 2 | $27 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Zyla Life Sciences, Inc. | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Braeburn Inc. | 1 | $14 |
| Merck | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QULIPTA$624
- UBRELVY$603
- NURTEC ODT$128
- AIMOVIG$116
How this compares
$4,756 in reported general payments places this provider in the 90th percentile of 618 physical medicine & rehabilitation providers in Florida.
See all physical medicine & rehabilitation providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 148 | $138,872 |
| OxycontinOxycodone Hcl | 140 | $125,526 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 550 | $115,209 |
| LinzessLinaclotide | 94 | $82,165 |
| UbrelvyUbrogepant | 31 | $80,572 |
| RelistorMethylnaltrexone Bromide | 31 | $78,853 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 1,502 | $63,382 |
| MovantikNaloxegol Oxalate | 62 | $35,338 |
| Nurtec OdtRimegepant Sulfate | 16 | $33,860 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,086 | $33,672 |
| QuliptaAtogepant | 18 | $31,913 |
| Buprenorphine | 120 | $28,197 |
| Morphine Sulfate ErMorphine Sulfate | 758 | $25,393 |
| Oxycodone Hcl | 1,084 | $20,991 |
| Fentanyl | 152 | $18,001 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Ubrelvy, Qulipta | $1,559 | $194,650143 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine, Morphine Sulfate | $21 | $151,525875 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca | $694 | $141,238159 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $426 | $78,85331 claims |
| PfizerNurtec Odt, Eliquis | $392 | $50,29341 claims |
| Redhill Biopharma Inc.Movantik | $69 | $35,33862 claims |
| Eisai Inc.Dayvigo | $58 | $3,54211 claims |
| Upsher-smith Laboratories LLCTopiramate | $46 | $2,60488 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 618 physical medicine & rehabilitation providers in Florida.
Other physical medicine & rehabilitation in Port Charlotte
- Michael RozakPort Charlotte$6K
- Anthony GiuffridaFort Lauderdale$271K
- Ryan HafnerSarasota$164K
- Cassandra ListJacksonville$154K
- Marissa McCarthyTampa$94K
- Jose Medina SanchezTampa$30K
- Alan MillerFernandina Beach$26K
- Anish SoniNaples$25K
- Jose de la TorreWesley Chapel$23K
- Kaivalya DeshpandeMiami$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.